OPTIRAY 300 Drug Patent Profile
✉ Email this page to a colleague
When do Optiray 300 patents expire, and what generic alternatives are available?
Optiray 300 is a drug marketed by Liebel-flarsheim and is included in two NDAs.
The generic ingredient in OPTIRAY 300 is ioversol. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the ioversol profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for OPTIRAY 300?
- What are the global sales for OPTIRAY 300?
- What is Average Wholesale Price for OPTIRAY 300?
Summary for OPTIRAY 300
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 73 |
Clinical Trials: | 3 |
Patent Applications: | 1,841 |
DailyMed Link: | OPTIRAY 300 at DailyMed |
Recent Clinical Trials for OPTIRAY 300
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Duke Clinical Research Institute | Phase 4 |
GE Healthcare | Phase 4 |
Bayer | Phase 4 |
Pharmacology for OPTIRAY 300
Drug Class | Radiographic Contrast Agent |
Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for OPTIRAY 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liebel-flarsheim | OPTIRAY 300 | ioversol | INJECTABLE;INJECTION | 019710-004 | Jan 22, 1992 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Liebel-flarsheim | OPTIRAY 300 | ioversol | INJECTABLE;INJECTION | 020923-004 | May 13, 1999 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for OPTIRAY 300
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Liebel-flarsheim | OPTIRAY 300 | ioversol | INJECTABLE;INJECTION | 019710-004 | Jan 22, 1992 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for OPTIRAY 300
See the table below for patents covering OPTIRAY 300 around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 3362967 | ⤷ Sign Up | |
Netherlands | 930067 | ⤷ Sign Up | |
Australia | 9151182 | ⤷ Sign Up | |
Canada | 1198739 | DERIVES DE 2,4,6-TRIIODOISOPHTALAMIDE (2,4,6-TRIIODOISOPHTHALAMIDE DERIVATIVE) | ⤷ Sign Up |
Australia | 552188 | ⤷ Sign Up | |
Japan | H0224252 | ⤷ Sign Up | |
Japan | S58131970 | COMPOUND | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for OPTIRAY 300
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0083964 | 93C0142 | Belgium | ⤷ Sign Up | PRODUCT NAME: IOVERSOL; NAT. REGISTRATION NO/DATE: 74 IS 56 F12/19910521; FIRST REGISTRATION: NL RVG 13345 19891016 |
0083964 | SPC/GB93/089 | United Kingdom | ⤷ Sign Up | SPC/GB93/089: 20041015 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |